The past, present and future of antifolates in the treatment of Plasmodium falciparum infection.

Chemotherapy remains the most important means of controlling malaria, one of the deadliest infectious parasitic diseases in the world. Antimalarial antifolates have been central for prophylaxis and treatment of malaria. This drug family was discovered in the 1940s, during the Second World War, and molecules that are currently in clinical use were discovered at that time. Since the 1940s, no new antimalarial antifolates have been developed that have reached Phase I/II stages. Limited work has been carried out to exploit the inhibition of the malaria folate pathway as a means of discovering new drugs. In this review, work carried out on antimalarial antifolates since the 1940s up to the present time is discussed in terms of discovery, clinical use, mode of action and mechanism of resistance. New concepts have been presented to improve antimalarial antifolate in vivo efficacy and to identify potent new antifolate agents.

[1]  Synthesis of substituted indole derivatives as a new class of antimalarial agents. , 2005, Bioorganic & medicinal chemistry letters.

[2]  K. Srivastava,et al.  Synthesis of substituted indole derivatives as a new class of antimalarial agents. , 2005, Bioorganic & medicinal chemistry letters.

[3]  C. Plowe,et al.  The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. , 1997, Parasitology today.

[4]  J. Golenser,et al.  Plasmodium falciparum: in vitro induction of resistance to aminopterin. , 1981, Experimental parasitology.

[5]  A. Dicko,et al.  Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. , 2005, The Journal of infectious diseases.

[6]  A. Sowunmi,et al.  Open randomized study of pyrimethamine–sulphadoxine vs. pyrimethamine–sulphadoxine plus probenecid for the treatment of uncomplicated Plasmodium falciparum malaria in children , 2004, Tropical medicine & international health : TM & IH.

[7]  C. Sibley,et al.  Efficacies of Lipophilic Inhibitors of Dihydrofolate Reductase against Parasitic Protozoa , 2001, Antimicrobial Agents and Chemotherapy.

[8]  David A. Fidock,et al.  Antimalarial drug discovery: efficacy models for compound screening , 2004, Nature Reviews Drug Discovery.

[9]  A. Nzila,et al.  Sulfa drugs strike more than once. , 2004, Trends in parasitology.

[10]  D. G. Davey,et al.  Studies on synthetic antimalarial drugs; some biguanide derivatives as new types of antimalarial substances with both therapeutic and causal prophylactic activity. , 1945, Annals of tropical medicine and parasitology.

[11]  T. Wellems,et al.  Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. E. Hyde,et al.  Comparative folate metabolism in humans and malaria parasites (part II): activities as yet untargeted or specific to Plasmodium. , 2005, Trends in parasitology.

[13]  N. Tomioka,et al.  Lead discovery of inhibitors of the dihydrofolate reductase domain of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase. , 1997, Biochemical and biophysical research communications.

[14]  J. E. Hyde,et al.  A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance , 1997, Parasitology.

[15]  R. Degowin,et al.  Clinical experience with sulphadiazine and pyrimethamine in the treatment of persons experimentally infected with chloroquine-resistant Plasmodium falciparum. , 1967, Annals of tropical medicine and parasitology.

[16]  E. Petersen.  Malaria chemoprophylaxis: when should we use it and what are the options? , 2004, Expert review of anti-infective therapy.

[17]  I. Sia,et al.  A trial of proguanil-dapsone in comparison with sulfadoxine-pyrimethamine for the clearance of Plasmodium falciparum infections in Tanzania. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[18]  A. Jung,et al.  Mechanisms of sulfadoxine resistance in Plasmodium falciparum. , 1986, Molecular and biochemical parasitology.

[19]  K. Srivastava,et al.  Antimalarial activity of 2,4,6-trisubstituted pyrimidines. , 2005, Bioorganic & medicinal chemistry letters.

[20]  J. Zurlo,et al.  Trimethoprim-sulfamethoxazole revisited. , 2003, Archives of internal medicine.

[21]  N. White,et al.  Artesunate-dapsone-proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[22]  A. Nzila,et al.  Therapeutic potential of folate uptake inhibition in Plasmodium falciparum. , 2004, Trends in parasitology.

[23]  C. Sibley,et al.  Novel alleles of Plasmodium falciparum dhfr that confer resistance to chlorcycloguanil. , 2005, Molecular and biochemical parasitology.

[24]  C. Sibley,et al.  Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania. , 2002, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[25]  G. Hitchings,et al.  Antagonists of nucleic acid derivatives. VI. Purines. , 1951, The Journal of biological chemistry.

[26]  W. Watkins,et al.  Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation. , 2005, The American journal of tropical medicine and hygiene.

[27]  W. Peters.  Malaria. Chemoprophylaxis and chemotherapy. , 1971, British medical journal.

[28]  A. Jackman.  Antifolate Drugs in Cancer Therapy , 1999, Cancer Drug Discovery and Development.

[29]  A. Cowman,et al.  Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[30]  K. Srivastava,et al.  Syntheses of 2,4,6-trisubstituted triazines as antimalarial agents. , 2005, Bioorganic & medicinal chemistry letters.

[31]  D. Banerjee,et al.  Resistance Mechanisms to Methotrexate in Tumors , 1996, Stem cells.

[32]  W. Peters.  Chemoprophylaxis and chemotherapy. , 1971 .

[33]  A. Nzila,et al.  Chemosensitization of Plasmodium falciparum by Probenecid In Vitro , 2003, Antimicrobial Agents and Chemotherapy.

[34]  A. Nzila,et al.  Molecular monitoring of the Leu-164 mutation of dihydrofolate reductase in a highly sulfadoxine/pyrimethamine-resistant area in Africa , 2003, Malaria Journal.

[35]  C. Plowe,et al.  Mechanisms of Resistance of Malaria Parasites to Antifolates , 2005, Pharmacological Reviews.

[36]  A. Sowunmi,et al.  Comparative effects of pyrimethamine–sulfadoxine, with and without probenecid, on Plasmodium falciparum gametocytes in children with acute, uncomplicated malaria , 2004, Annals of tropical medicine and parasitology.

[37]  Yongyuth Yuthavong,et al.  Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities. , 2004, Journal of medicinal chemistry.

[38]  A. Cowman,et al.  Functional genomics: identifying drug targets for parasitic diseases. , 2003, Trends in parasitology.

[39]  W. Sirawaraporn,et al.  Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum. , 2002, Journal of medicinal chemistry.

[40]  W. Watkins,et al.  The antimalarial triazine WR99210 and the prodrug PS-15: folate reversal of in vitro activity against Plasmodium falciparum and a non-antifolate mode of action of the prodrug. , 1999, The American journal of tropical medicine and hygiene.

[41]  J. E. Hyde,et al.  Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy. , 2005, Trends in parasitology.

[42]  Yongyuth Yuthavong,et al.  Stoichiometric selection of tight-binding inhibitors by wild-type and mutant forms of malarial (Plasmodium falciparum) dihydrofolate reductase. , 2005, Analytical chemistry.

[43]  Yongyuth Yuthavong,et al.  Novel antifolate resistant mutations of Plasmodium falciparum dihydrofolate reductase selected in Escherichia coli. , 2002, Molecular and biochemical parasitology.

[44]  J. E. Hyde,et al.  Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization , 1997, Molecular microbiology.

[45]  I. Adagu,et al.  Co-trimoxazole compared with sulfadoxine-pyrimethamine in the treatment of uncomplicated malaria in Kenyan children. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[46]  M. Walkinshaw,et al.  Characterization, crystallization and preliminary X-ray analysis of bifunctional dihydrofolate reductase-thymidylate synthase from Plasmodium falciparum. , 2004, Acta crystallographica. Section D, Biological crystallography.

[47]  F. M. Hanes.  DIAGNOSTIC CRITERIA AND RESISTANCE TO THERAPY IN THE SPRUE SYNDROME , 1942 .

[48]  D. G. Davey,et al.  A Metabolite of ‘Paludrine’ with High Antimalarial Activity , 1951, Nature.

[49]  A. Sowunmi,et al.  Comparative efficacy of chloroquine and cotrimoxazole in the treatment of acute uncomplicated falciparum malaria in Nigerian children. , 2002, The Central African journal of medicine.

[50]  S. Chusacultanachai,et al.  Malarial (Plasmodium falciparum) dihydrofolate reductase-thymidylate synthase: structural basis for antifolate resistance and development of effective inhibitors , 2004, Parasitology.

[51]  S. Krungkrai,et al.  Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. , 1992, Biochemical pharmacology.

[52]  T. Holtz,et al.  Efficacy of trimethoprim-sulfamethoxazole compared with sulfadoxine-pyrimethamine plus erythromycin for the treatment of uncomplicated malaria in children with integrated management of childhood illness dual classifications of malaria and pneumonia. , 2005, The American journal of tropical medicine and hygiene.

[53]  K. Srivastava,et al.  Antimalarial activity and synthesis of new trisubstituted pyrimidines. , 2005, Bioorganic & medicinal chemistry letters.

[54]  Yongyuth Yuthavong,et al.  Basis for antifolate action and resistance in malaria. , 2002, Microbes and infection.

[55]  W. Sirawaraporn,et al.  Pyrimethamine analogs as strong inhibitors of double and quadruple mutants of dihydrofolate reductase in human malaria parasites. , 2003, Organic & biomolecular chemistry.

[56]  K. Kain,et al.  Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  P. Rathod,et al.  Selection and characterization of 5-fluoroorotate-resistant Plasmodium falciparum , 1994, Antimicrobial Agents and Chemotherapy.

[58]  A. Sowunmi,et al.  Plasmodium falciparum hyperparasitaemia in children. Risk factors, treatment outcomes, and gametocytaemia following treatment. , 2004, Parasite.

[59]  D. Warhurst,et al.  Novel alleles of the Plasmodium falciparum dhfr highly resistant to pyrimethamine and chlorcycloguanil, but not WR99210. , 2001, Molecular and biochemical parasitology.

[60]  T. Triglia,et al.  Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[61]  W. Watkins,et al.  Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[62]  P. Rathod,et al.  Potent and Selective Activity of a Combination of Thymidine and 1843U89, a Folate-Based Thymidylate Synthase Inhibitor, against Plasmodium falciparum , 2000, Antimicrobial Agents and Chemotherapy.

[63]  R. Black.  Malaria in the Australian army in South Vietnam: successful use of a proguanil-dapsone combination for chemoprophylaxis of chloroquine-resistant falciparum malaria. , 1973, The Medical journal of Australia.

[64]  J. E. Hyde,et al.  Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine‐resistant malaria , 1998, The EMBO journal.

[65]  A. Hall,et al.  Comparison of diaminodiphenylsulphonepyrimethamine and sulfadoxine-pyrimethamine combinations in the treatment of falciparum malaria in Thailand. , 1975, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[66]  D. Koech,et al.  INADEQUACY OF CHLORPROGUANIL 20 mg PER WEEK AS CHEMOPROPHYLAXIS FOR FALCIPARUM MALARIA IN KENYA , 1987, The Lancet.

[67]  M. Hurly.  Potentiation of pyrimethamine by sulphadiazine in human malaria. , 1959, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[68]  Z. Premji,et al.  Rare, highly pyrimethamine-resistant alleles of the Plasmodium falciparum dihydrofolate reductase gene from 5 African sites. , 2004, The Journal of infectious diseases.

[69]  K. Rieckmann,et al.  Effects of diaphenylsulphone (dapsone) against Plasmodium vivax of South West Pacific origin. , 1968, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[70]  H. Webster,et al.  Malaria chemoprophylaxis using proguanil/dapsone combinations on the Thai-Cambodian border. , 1992, The American journal of tropical medicine and hygiene.

[71]  K. Rieckmann,et al.  Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials. , 2001, Journal of medicinal chemistry.

[72]  G. E. Foster,et al.  THE TREATMENT OF STREPTOCOCCAL INFECTIONS IN MICE WITH 4:4'DIAMINODIPHENYLSULPHONE , 1937 .

[73]  E. Nduati,et al.  Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. , 2000, The Journal of infectious diseases.

[74]  Giulio Rastelli,et al.  Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach. , 2004, Journal of medicinal chemistry.

[75]  J. Critchley,et al.  Chlorproguanil-dapsone for treating uncomplicated malaria. , 2004, The Cochrane database of systematic reviews.

[76]  C. Sibley,et al.  Mutagenesis of dihydrofolate reductase from Plasmodium falciparum: analysis in Saccharomyces cerevisiae of triple mutant alleles resistant to pyrimethamine or WR99210. , 2001, Molecular and biochemical parasitology.

[77]  T. Triglia,et al.  The mechanism of resistance to sulfa drugs in Plasmodium falciparum. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[78]  J. E. Hyde,et al.  The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. , 1990, Pharmacology & therapeutics.

[79]  E. Nduati,et al.  Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania , 2001, The Lancet.

[80]  J. Kublin,et al.  Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. , 2002, The Journal of infectious diseases.

[81]  G. Peters,et al.  Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. , 1999, Cancer research.

[82]  A. Breckenridge,et al.  In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs , 1995, Antimicrobial agents and chemotherapy.

[83]  E. Stokstad,et al.  SYNTHESIS OF A COMPOUND IDENTICAL WITH THE L. CASEI FACTOR ISOLATED FROM LIVER. , 1945, Science.

[84]  M. Kris,et al.  A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors , 2006, Cancer Chemotherapy and Pharmacology.

[85]  G. Hitchings,et al.  ANTAGONISTS OF NUCLEIC ACID DERIVATIVES I. THE LACTOBACILLUS CASEI MODEL , 1950 .

[86]  A. E. Yeo,et al.  Activity of PS-15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo-in vitro model. , 1996, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[87]  B. Sharp,et al.  Intercontinental Spread of Pyrimethamine-Resistant Malaria , 2004, Science.

[88]  D. Fidock,et al.  Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[89]  P. Rathod,et al.  Selective activity of 5-fluoroorotic acid against Plasmodium falciparum in vitro , 1989, Antimicrobial Agents and Chemotherapy.

[90]  S. Bahr,et al.  In vitro activities of the biguanide PS-15 and its metabolite, WR99210, against cycloguanil-resistant Plasmodium falciparum isolates from Thailand , 1997, Antimicrobial agents and chemotherapy.

[91]  D. Wallace.  MALARIA IN THE AUSTRALIAN ARMY IN SOUTH VIETNAM , 1973, The Medical journal of Australia.

[92]  W. Sirawaraporn,et al.  Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum. , 2000, Journal of medicinal chemistry.

[93]  P. Rathod,et al.  Molecular targets of 5-fluoroorotate in the human malaria parasite, Plasmodium falciparum , 1992, Antimicrobial Agents and Chemotherapy.

[94]  W. Peters,et al.  Chemotherapy and drug resistance in malaria. , 1970 .

[95]  K. Marsh,et al.  Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range. , 1997, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[96]  K. Srivastava,et al.  Synthesis of 2,4,6-trisubstituted pyrimidines as antimalarial agents. , 2005, Bioorganic & medicinal chemistry.

[97]  D. Kyle,et al.  Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand. , 1997, Annals of Tropical Medicine and Parasitology.

[98]  I. Bygbjerg,et al.  Response of Plasmodium falciparum to cotrimoxazole therapy: relationship with plasma drug concentrations and dihydrofolate reductase and dihydropteroate synthase genotypes. , 2005, The American journal of tropical medicine and hygiene.

[99]  I. McGregor,et al.  Pyrimethamine and Sulphadiazine in Treatment of Malaria , 1963, British medical journal.

[100]  D. L. Jagt,et al.  In vitro susceptibilities of Plasmodium falciparum to compounds which inhibit nucleotide metabolism , 1990, Antimicrobial Agents and Chemotherapy.

[101]  Yongyuth Yuthavong,et al.  Insights into antifolate resistance from malarial DHFR-TS structures , 2003, Nature Structural Biology.

[102]  R. Michel.  [Comparative study of the association of sulfalene and pyrimethamine and of sulfalene alone in mass chemoprophylaxis of malaria]. , 1968, Medecine tropicale : revue du Corps de sante colonial.

[103]  W. Sirawaraporn,et al.  Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[104]  N. Saravia,et al.  Frequency of the Asn-108 and Thr-108 point mutations in the dihydrofolate reductase gene in Plasmodium falciparum from southwest Colombia. , 1998, The American journal of tropical medicine and hygiene.

[105]  C. Plowe,et al.  Kenyan Plasmodium falciparum Field Isolates: Correlation between Pyrimethamine and Chlorcycloguanil Activity In Vitro and Point Mutations in the Dihydrofolate Reductase Domain , 1998, Antimicrobial Agents and Chemotherapy.

[106]  D. Greenwood.  Conflicts of interest: the genesis of synthetic antimalarial agents in peace and war. , 1995, The Journal of antimicrobial chemotherapy.

[107]  J. E. Hyde,et al.  Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? , 2001, Trends in parasitology.

[108]  S. Jaffar,et al.  Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[109]  Kevin Marsh,et al.  In Vitro Activities of 2,4-Diaminoquinazoline and 2,4-Diaminopteridine Derivatives against Plasmodium falciparum , 2004, Antimicrobial Agents and Chemotherapy.

[110]  P. Rathod,et al.  Divergent Regulation of Dihydrofolate Reductase Between Malaria Parasite and Human Host , 2002, Science.

[111]  W. Peters,et al.  The antimalarial activity of N-benzyloxydihydrotriazines. I. The activity of clociguanil (BRL 50216) against rodent malaria, and studies on its mode of action. , 1980, Annals of tropical medicine and parasitology.

[112]  R. Girdwood,et al.  Folic acid in the treatment of the sprue syndrome. , 1947, Lancet.

[113]  B. Bergmann,et al.  Pyrimethamin-resistantPlasmodium falciparum lack cross-resistance to methotrexate and 2,4-diamino-5-(substituted benzyl) pyrimidines , 2004, Parasitology Research.

[114]  J. Wolff,et al.  Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. , 1948, The New England journal of medicine.

[115]  E. Nduati,et al.  2,4-Diaminopteridine-Based Compounds as Precursors for De Novo Synthesis of Antifolates: a Novel Class of Antimalarials , 2005, Antimicrobial Agents and Chemotherapy.

[116]  G. Hitchings,et al.  2:4-diaminopyrimidines- a new series of antimalarials. , 1951, British journal of pharmacology and chemotherapy.

[117]  W. Milhous,et al.  Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[118]  Yongyuth Yuthavong,et al.  Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum. , 2004, Journal of medicinal chemistry.

[119]  P. Rathod,et al.  Susceptibility of Plasmodium falciparum to a combination of thymidine and ICI D1694, a quinazoline antifolate directed at thymidylate synthase , 1994, Antimicrobial Agents and Chemotherapy.

[120]  A. Hoffbrand,et al.  The history of folic acid , 2001, British journal of haematology.

[121]  J. Hyde,et al.  Translational up-regulation of antifolate drug targets in the human malaria parasite Plasmodium falciparum upon challenge with inhibitors. , 2004, Molecular and biochemical parasitology.

[122]  W. Watkins,et al.  Antagonism of sulfadoxine and pyrimethamine antimalarial activity in vitro by p-aminobenzoic acid, p-aminobenzoylglutamic acid and folic acid. , 1985, Molecular and biochemical parasitology.

[123]  W. Milhous,et al.  PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. , 1993, The American journal of tropical medicine and hygiene.

[124]  K. Kain,et al.  Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[125]  E. Nduati,et al.  Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[126]  A. Laing.  Studies on the chemotherapy of malaria. I. The treatment of overt falciparum malaria with potentiating combinations of pyrimethamine and sulphormethoxine or dapsone in The Gambia. , 1970, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[127]  W. Sirawaraporn,et al.  Mutational analysis of Plasmodium falciparum dihydrofolate reductase: the role of aspartate 54 and phenylalanine 223 on catalytic activity and antifolate binding. , 2002, Molecular and biochemical parasitology.